Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Guizhounli Pharmaceutical Co's interest expense for the
three
months ended in Mar. 2026 was ¥ -5 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-13 Mil.
Guizhounli Pharmaceutical Co (SHSE:603439) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Guizhounli Pharmaceutical Co Interest Expense Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guizhounli Pharmaceutical Co Interest Expense Chart
Guizhounli Pharmaceutical Co Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guizhounli Pharmaceutical Co (SHSE:603439) has a Interest Expense of ¥-13 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Guizhounli Pharmaceutical Co and its competitors.
Is Guizhounli Pharmaceutical Co's Interest Expense too high?
Guizhounli Pharmaceutical Co's current Interest Expense is ¥-13 Mil. Overall, Guizhounli Pharmaceutical Co has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guizhounli Pharmaceutical Co's Interest Expense compare to ZTS?
Guizhounli Pharmaceutical Co's Interest Expense of ¥-13 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Guizhounli Pharmaceutical Co and its competitors. Guizhounli Pharmaceutical Co's current Interest Expense is ¥-13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guizhounli Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co (SHSE:603439) is currently considered Fairly Valued. The stock's GF Value™ is ¥11.62, compared to a current price of ¥12.65 — trading 8.9% above its estimated fair value. The current Interest Expense is ¥-13 Mil. Guizhounli Pharmaceutical Co's overall GF Score™ is 93/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Guizhounli Pharmaceutical Co (SHSE:603439), the current Interest Expense is ¥-13 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guizhounli Pharmaceutical Co (SHSE:603439) Overvalued in 2026?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥12.65 is trading 8.9% above its estimated GF Value™ of ¥11.62.
GuruFocus considers Guizhounli Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:603439:
Interest Expense: ¥-13 Mil
GF Value™: ¥11.62 vs. price of ¥12.65 (8.9% above fair value)
No single metric tells the full story. See the SHSE:603439 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
93GF Score
Get the complete analysis for SHSE:603439
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603439 has been successfully added to your 
